This page has not been authorized, sponsored, or otherwise approved or endorsed by the companies represented herein. Each of the company logos represented herein are trademarks of Microsoft Corporation; Dow Jones & Company; Nasdaq, Inc.; Forbes Media, LLC; Investor's Business Daily, Inc.; and Morningstar, Inc.
Copyright 2025 Zacks Investment Research | 101 N Wacker Drive, Floor 15, Chicago, IL 60606
At the center of everything we do is a strong commitment to independent research and sharing its profitable discoveries with investors. This dedication to giving investors a trading advantage led to the creation of our proven Zacks Rank stock-rating system. Since 1988 it has more than doubled the S&P 500 with an average gain of +23.75% per year. These returns cover a period from January 1, 1988 through July 7, 2025. Zacks Rank stock-rating system returns are computed monthly based on the beginning of the month and end of the month Zacks Rank stock prices plus any dividends received during that particular month. A simple, equally-weighted average return of all Zacks Rank stocks is calculated to determine the monthly return. The monthly returns are then compounded to arrive at the annual return. Only Zacks Rank stocks included in Zacks hypothetical portfolios at the beginning of each month are included in the return calculations. Zacks Ranks stocks can, and often do, change throughout the month. Certain Zacks Rank stocks for which no month-end price was available, pricing information was not collected, or for certain other reasons have been excluded from these return calculations. Zacks may license the Zacks Mutual Fund rating provided herein to third parties, including but not limited to the issuer.
Visit Performance Disclosure for information about the performance numbers displayed above.
Visit www.zacksdata.com to get our data and content for your mobile app or website.
Real time prices by BATS. Delayed quotes by Sungard.
NYSE and AMEX data is at least 20 minutes delayed. NASDAQ data is at least 15 minutes delayed.
This site is protected by reCAPTCHA and the Google Privacy Policy, DMCA Policy and Terms of Service apply.
View All Zacks #1 Ranked Stocks
Zacks News
Headquartered in Natick, MA and founded in 1979, Boston Scientific Corporation manufactures medical devices and products used in various interventional medical specialties worldwide. The company has adopted the organic as well as inorganic routes for success. Boston Scientific currently has 3 global reportable segments viz. Cardiovascular (39.6% of total revenue in 2019; up 10% organically from 2018), Rhythm and Neuro (28.1%; up 1%) and MedSurg (30.2%; up 10.6%).
Veracyte Gains 44% in a Year: What's Driving the Stock?
by Zacks Equity Research
VCYT is gaining shares due to the strength of its Afirma and Decipher tests.
BVS Stock Gains Post Divestiture of Advanced Rehabilitation Business
by Zacks Equity Research
Bioventus aims to improve its focus and execution within its core businesses and enhance liquidity following the divestiture.
Reasons to Retain Inari Medical Stock in Your Portfolio for Now
by Zacks Equity Research
NARI continues to gain from its expanded product portfolio. The company's expansion in China and Japan bodes well.
5 Non-Tech Outperformers of 2024 Set to Fly Higher in the Near Term
by Nalak Das
Five non-technology high-flyers of 2024 have the potential to fly higher in the short term. These are: CMG, IBKR, KKR, FI, BSX.
Phibro Animal Health Gains 83% in a Year: What's Driving the Stock?
by Zacks Equity Research
PAHC shares gain owing to the remarkable performance of the Animal Health business and potential in the emerging markets.
McKesson Stock Declines Post Divestiture of Canada-Based Businesses
by Zacks Equity Research
MCK aims to focus on capital deployment and prioritize investments to strengthen its strategic oncology and biopharma growth platforms.
Should You Retain Charles River Stock in Your Portfolio Now?
by Zacks Equity Research
CRL's solid prospects in the RMS segment and solid financial stability create a favorable outlook for investors.
Is Boston Scientific Stock a Smart Pick for Your Portfolio Right Now?
by Zacks Equity Research
Investors continue to be optimistic about BSX, courtesy of its international expansion efforts and WATCHMAN's performance.
Why Boston Scientific (BSX) is Poised to Beat Earnings Estimates Again
by Zacks Equity Research
Boston Scientific (BSX) has an impressive earnings surprise history and currently possesses the right combination of the two key ingredients for a likely beat in its next quarterly report.
Boston Scientific (BSX) Stock Moves -0.4%: What You Should Know
by Zacks Equity Research
Boston Scientific (BSX) closed the most recent trading day at $89.32, moving -0.4% from the previous trading session.
Should You Hold Quest Diagnostics Stock in Your Portfolio Now?
by Zacks Equity Research
DGX's strength in the base business and the robust adoption of Advanced Diagnostics services bode well.
Boston Scientific (BSX) Falls More Steeply Than Broader Market: What Investors Need to Know
by Zacks Equity Research
In the closing of the recent trading day, Boston Scientific (BSX) stood at $89.68, denoting a -1.08% change from the preceding trading day.
PBH vs. BSX: Which Stock Is the Better Value Option?
by Zacks Equity Research
PBH vs. BSX: Which Stock Is the Better Value Option?
5 MedTech Stocks That Are Poised to Beat the Market in 2025
by Harshit Gupta
Here, we discuss five stocks that are likely to generate better than the market, driven by strong demand for existing products and the addition of innovative new devices.
How to Boost Your Portfolio with Top Medical Stocks Set to Beat Earnings
by Zacks Equity Research
Investors looking for ways to find stocks that are set to beat quarterly earnings estimates should check out the Zacks Earnings ESP.
5 Top AI-in-MedTech Stocks for Big Gains in 2025: MDT, BSX & More
by Indrajit Bandyopadhyay
Here we discuss five medical stocks - MDT, BSX, BDX, GEHC and TEM - incorporating AI in their workflows. These are likely to gain in 2025 as AI helps cut costs and improve patient care.
Should You Hold Align Technology Stock in Your Portfolio Right Now?
by Zacks Equity Research
ALGN stock stays on investors' radar, courtesy of its strong Invisalign potential and success with iTero.
Is Abbott Stock Worth Buying at a Discounted P/S Valuation?
by Urmimala Biswas
Abbott's strong market position, promising growth prospects and consistent share gains make it a compelling pick for investors.
Should Prestige Consumer Stock Stay in Your Portfolio Right Now?
by Zacks Equity Research
Investors remain optimistic about PBH stock due to its strong focus on brand building.
Why Boston Scientific (BSX) Outpaced the Stock Market Today
by Zacks Equity Research
In the most recent trading session, Boston Scientific (BSX) closed at $91.07, indicating a +1.35% shift from the previous trading day.
4 Healthcare Stocks Rising More Than 50% in 2024 With Room to Grow
by Debasmita Chatterjee
Medical stocks are expected to reap the benefits of affordable health insurance plans, rising surgeries and widespread adoption of telehealth services in the days ahead. However, inflation and supply-chain woes may act as spoilsport.
Boston Scientific (BSX) Rises Higher Than Market: Key Facts
by Zacks Equity Research
Boston Scientific (BSX) reachead $89.86 at the closing of the latest trading day, reflecting a +1.02% change compared to its last close.
Should You Retain Teleflex Stock in Your Portfolio Right Now?
by Zacks Equity Research
TFX stays on investors' radars due to its performance in the Vascular Access segment and expansion moves.
Medtronic Stock Declines 5.6% in a Month: Time to Buy the Dip?
by Urmimala Biswas
MDT stock suffers as a result of geopolitical complications and supply issues despite an expanding portfolio and strong strategic executions.
All You Need to Know About Boston Scientific (BSX) Rating Upgrade to Buy
by Zacks Equity Research
Boston Scientific (BSX) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #2 (Buy).